Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency

  title={Cost-Effectiveness Analysis of a National Newborn Screening Program for Biotinidase Deficiency},
  author={Laura Vallejo-Torres and Iv{\'a}n Castilla and Mar{\'i}a Luz Couce and Celia P{\'e}rez-Cerd{\'a} and Elena Mart{\'i}n‐Hern{\'a}ndez and M Pineda and Jaume Campistol and Arantzazu Arrospide and Stephen Morris and Pedro Serrano-Aguilar},
  pages={e424 - e432}
BACKGROUND AND OBJECTIVES: There are conflicting views as to whether testing for biotinidase deficiency (BD) ought to be incorporated into universal newborn screening (NBS) programs. The aim of this study was to evaluate the cost-effectiveness of adding BD to the panel of conditions currently screened under the national NBS program in Spain. METHODS: We used information from the regional NBS program for BD that has been in place in the Spanish region of Galicia since 1987. These data, along… 

Figures and Tables from this paper

Economic evaluation of point of care universal newborn screening for glucose-6-Phosphate dehydrogenase deficiency in United States.
  • Ramesh Vidavalur, V. Bhutani
  • Medicine, Political Science
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2021
At incremental cost-effective threshold of $100,000/life year, pre-discharge screening would be expected to prove cost effective in preventing EHB related morbidities and mortality attributed to G6PD deficiency.
Frequency of biotinidase gene variants and incidence of biotinidase deficiency in the Newborn Screening Program in Minas Gerais, Brazil
Newborn screening for biotinidase deficiency, which revealed a higher incidence in Minas Gerais, is feasible and plays a critical role in the early identification of affected neonates and prevention of symptoms and irreversible sequelae.
The Further Adventures of Newborn Screening for Biotinidase Deficiency: Where It Is at and What We Still Need to Know
Based on the successful outcomes of older adolescents and adults with profound biotinidase deficiency identified by newborn screening, this is one of the best disorders for which to perform newborn screening.
Neonatal screening for biotinidase deficiency: A 30-year single center experience
Cost-Effectiveness Methods and Newborn Screening Assessment.
In this chapter, a general overview of current economic evaluation methods and the challenges for their application to newborn screening programs is provided.
The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review
The results of this review can support future economic evaluation research, aiding researchers to develop a methodological guidance to perform EEs aimed at producing solid results to inform decisions for resource allocation in neonatal screening.
Neonatal screening for profound biotinidase deficiency in the Netherlands: consequences and considerations
It is concluded that neonatal screening for profound biotinidase produces a high number of false positives, and the screening threshold might be reduced to 15%.
Clinical Indications and Outcome of Biotinidase Deficiency Screening among Children and Youths in a Scottish NHS Region Between 2014 and 2016
The pattern and outcome of investigations for BTD among children and young people in a Scottish NHS Board and a substantial proportion of the patients could not be analysed due to various problems with their blood samples is analyzed.
Genotypic and phenotypic correlations of biotinidase deficiency in the Chinese population
The phenotype of biotinidase deficiency in this cohort is delineated and differences in the genotype and phenotype compared with those in Western countries are highlighted.
Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics
These guidelines were developed to define and standardize laboratory procedures for enzymatic biotinidase testing, to delineate situations for which follow-up molecular testing is warranted, and to characterize variables that can influence test performance and interpretation of results.


Comprehensive Cost-Utility Analysis of Newborn Screening Strategies
The results found in the base-case analysis were stable across variations in nearly all variables, and over the long term, funding comprehensive newborn screening programs is likely to save money for society.
Outcome in patients with profound biotinidase deficiency: relevance of newborn screening
There was no significant difference in social adaptation or behavioural problems between symptomatic and asymptomatic children, and children with PBD established presymptomatically following newborn screening and treated with biotin supplementation, do not experience these effects.
Prospective ascertainment of complete and partial serum biotinidase deficiency in the newborn
The variant allele(s) for biotinidase deficiency was more common in French Canadians than in other ethnic groups in Quebec; there was no evidence of regional clustering or founder effect.
High frequencies of biotinidase (BTD) gene mutations in the Hungarian population
The results demonstrate that the frequencies of two of the most common biotinidase variant alleles are higher in the Hungarian population than in other Caucasian populations and this and the presence of a unique Hungarian mutation may explain the high incidence of biotininidase deficiency in Hungary.
The magnitude and challenge of false-positive newborn screening test results.
The magnitude of false-positive results generated in newborn screening programs, particularly for congenital endocrinopathies, presents a great challenge for future improvement of this important public health program.
Evaluation of population newborn screening practices for rare disorders in member states of the European Union
As a result of a tender launched by the European Commission, an activity has started with the aims of identifying and evaluating all aspects deemed relevant to the implementation of a public health
Worldwide survey of neonatal screening for biotinidase deficiency
  • B. Wolf
  • Medicine, Biology
    Journal of Inherited Metabolic Disease
  • 2005
Neonatal screening for biotinidase deficiency has been conducted in 14 countries since 1984 and an estimated 1 in 123 individuals is heterozygous for the disorder.
Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria
Subdivision of the group of patients with profound biotinidase deficiency suggests that only patients with residual activities <1% are prone to develop clinical symptoms early in life, while patients with remnant activities >1% may remain asymptomatic even without treatment, as do patients with partial deficiency.